{"id":"bhv3241-verdiperstat","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting NOX2, BHV3241 reduces the production of reactive oxygen species (ROS) in microglia, which are a type of immune cell in the brain. This reduction in ROS production is thought to be beneficial in treating neurodegenerative diseases such as multiple system atrophy (MSA).","oneSentence":"BHV3241, also known as verdiperstat, is a small molecule inhibitor of the enzyme NADPH oxidase 2 (NOX2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:58:08.734Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple system atrophy (MSA)"}]},"trialDetails":[{"nctId":"NCT05184569","phase":"PHASE1","title":"Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology","status":"RECRUITING","sponsor":"Peter Ljubenkov, MD","startDate":"2022-04-14","conditions":"Semantic Dementia","enrollment":64},{"nctId":"NCT03952806","phase":"PHASE3","title":"Study of BHV-3241 in Participants With Multiple System Atrophy","status":"COMPLETED","sponsor":"Biohaven Pharmaceuticals, Inc.","startDate":"2019-07-29","conditions":"Multiple System Atrophy","enrollment":421},{"nctId":"NCT05086094","phase":"","title":"Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)","status":"NO_LONGER_AVAILABLE","sponsor":"Biohaven Pharmaceuticals, Inc.","startDate":"","conditions":"Multiple System Atrophy (MSA)","enrollment":""},{"nctId":"NCT04616456","phase":"EARLY_PHASE1","title":"Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-12-30","conditions":"Multiple System Atrophy, Multiple System Atrophy, Cerebellar Variant, Multiple System Atrophy, Parkinson Variant (Disorder)","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BHV3241, verdiperstat","genericName":"BHV3241, verdiperstat","companyName":"Biohaven Pharmaceuticals, Inc.","companyId":"biohaven-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BHV3241, also known as verdiperstat, is a small molecule inhibitor of the enzyme NADPH oxidase 2 (NOX2). Used for Multiple system atrophy (MSA).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}